Trial Profile
A Multicenter, Open Label, Randomized, Parallel-Group Study to Evaluate the Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis With Inadequate Response to at Least One Disease Modifying Anti Rheumatic Drugs (DMARD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Masitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 23 Jun 2009 Results have been published in full in Arthritis Research & Therapy (vol 11: R95, No. 3).
- 04 Feb 2009 New trial record